Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects

被引:35
|
作者
Veronese, FD
Arnott, D
Barnaba, V
Loftus, DJ
Sakaguchi, K
Thompson, CB
Salemi, S
Mastroianni, C
Sette, A
Shabanowitz, J
Hunt, DF
Appella, E
机构
[1] NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892
[2] NCI,TUMOR CELL BIOL LAB,NIH,BETHESDA,MD 20892
[3] UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903
[4] UNIV ROMA LA SAPIENZA,CATTEDRA MED INTERNA,MED CLIN 1,I-00161 ROME,ITALY
[5] UNIV ROMA LA SAPIENZA,DEPT MALATTIE INFETT & TROP,I-00161 ROME,ITALY
[6] ADV BIOSCI LABS INC,KENSINGTON,MD 20895
[7] CYTEL CORP,DEPT IMMUNOL,SAN DIEGO,CA 92121
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 1996年 / 183卷 / 06期
关键词
D O I
10.1084/jem.183.6.2509
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A subtractive analysis of peptides eluted from major histocompatibility complex (MHC) class I human histocompatibility leukocyte antigen (HLA)-A2.1 molecules purified from either human immunodeficiency virus type-1 (HIV-1)-infected or uninfected cells was performed using micro high-performance liquid chromatography and mass spectrometry. Three peptides unique to infected cells were identified and found to derive from a single protein, human vinculin, a structural protein not known to be involved in viral pathogenesis. Molecular and cytofluorometric analyses revealed vinculin mRNA and vinculin protein overexpression in B and T lymphocytes from HIV-1-infected individuals. Vinculin peptide-specific CTL activity was readily elicited from peripheral blood lymphocytes of the majority of HLA-A2.1(+), HIV+ patients tested. Our observations suggest that atypical vinculin expression and MHC class I-mediated presentation of vinculin-derived peptides accompany HIV infection of lymphoid cells in vivo, with a resultant induction of antivinculin CTL in a significant portion of HIV+ (HLA-A2.1(+)) individuals.
引用
收藏
页码:2509 / 2516
页数:8
相关论文
共 50 条
  • [31] Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children
    Luzuriaga, K
    Bryson, Y
    McSherry, G
    Robinson, J
    Stechenberg, B
    Scott, G
    Lamson, M
    Cort, S
    Sullivan, JL
    JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04): : 713 - 721
  • [32] Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children
    Kalyesubula, I
    MusokeMudido, P
    Marum, L
    Bagenda, D
    Aceng, E
    Ndugwa, C
    Olness, K
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (09) : 876 - 881
  • [33] An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes
    Xia Jin
    Graham Ogg
    Sabstian Bonhoeffer
    Jeffrey Safrit
    Mika Vesanen
    Daniel Bauer
    Donald Chen
    Yunzhen Cao
    Marie-Ange Demoitie
    Linqi Zhang
    Martin Markowitz
    Douglas Nixon
    Andrew McMichael
    David D. Ho
    Molecular Medicine, 2000, 6 : 803 - 809
  • [34] Entamoeba gingivalis in human immunodeficiency virus type 1-infected patients with periodontal disease
    Lucht, E
    Evengård, B
    Skott, J
    Pehrson, P
    Nord, CE
    CLINICAL INFECTIOUS DISEASES, 1998, 27 (03) : 471 - 473
  • [35] Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes
    Yang, OO
    Nguyen, PT
    Kalams, SA
    Dorfman, T
    Göttlinger, HG
    Stewart, S
    Chen, ISY
    Threlkeld, S
    Walker, BD
    JOURNAL OF VIROLOGY, 2002, 76 (04) : 1626 - 1631
  • [36] An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes
    Jin, X
    Ogg, G
    Bonhoeffer, S
    Safrit, J
    Vesanen, M
    Bauer, D
    Chen, D
    Cao, YZ
    Demoitie, MA
    Zhang, LQ
    Markowitz, M
    Nixon, D
    McMichael, A
    Ho, DD
    MOLECULAR MEDICINE, 2000, 6 (09) : 803 - 809
  • [37] Antiphospholipid syndrome in a human immunodeficiency virus 1-infected child
    Shah, I
    Chudgar, P
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (02) : 185 - 186
  • [38] Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
    Burger, DM
    van Rossum, AMC
    Hugen, PWH
    Suur, MH
    Hartwig, NG
    Geelen, SPM
    Scherpbier, HJ
    Hoetelmans, RMW
    Vulto, AG
    de Groot, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 701 - 705
  • [39] STREPTOCOCCUS-PNEUMONIAE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED CHILDREN
    GESNER, M
    DESIDERIO, D
    KIM, M
    KAUL, A
    LAWRENCE, R
    CHANDWANI, S
    POLLACK, H
    RIGAUD, M
    KRASINSKI, K
    BORKOWSKY, W
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (08) : 697 - 703
  • [40] CLINICAL PHARMACOKINETICS OF ADEFOVIR IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PATIENTS
    CUNDY, KC
    BARDITCHCROVO, P
    WALKER, RE
    COLLIER, AC
    EBELING, D
    TOOLE, J
    JAFFE, HS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) : 2401 - 2405